DFB Healthcare Acquisitions Corp. — Form 10-Q Summary
Note: The supplied filing identifies the registrant as DFB Healthcare Acquisitions Corp., not AdaptHealth Corp. This summary reflects the filing text provided.
Business Context and Reporting Period
The filing covers the three months ended March 31, 2019 and was filed May 14, 2019. DFB Healthcare Acquisitions Corp. was a blank-check company formed to pursue a business combination, with an initial focus on healthcare and healthcare-related businesses. It had not commenced operating activities and had generated no operating revenue as of March 31, 2019.
The company completed its $250.0 million initial public offering in February 2018 and placed substantially all related proceeds in a trust account. It was required to complete a business combination by February 21, 2020 or liquidate and redeem the public shares.
Financial Performance, Cash Flow, Liquidity and Capitalization
| Metric | Three Months Ended March 31, 2019 | Three Months Ended March 31, 2018 |
|---|---|---|
| Operating revenue | None | None |
| General and administrative expense | $291,443 | $50,709 |
| State franchise taxes | $49,915 | $21,818 |
| Loss from operations | $(341,358) | $(72,527) |
| Interest income | $1,464,039 | $364,909 |
| Income tax expense | $297,083 | $72,049 |
| Net income | $825,598 | $220,333 |
| Net income per public share | $0.03 | $0.01 |
| Net cash used in operating activities | $(360,587) | $(380,187) |
Profitability was driven entirely by interest income on trust-account investments rather than business operations. Operating margins are not meaningful because the company had no operating revenue.
- Cash and cash equivalents outside the trust account were $744,766 at March 31, 2019, down from $947,098 at December 31, 2018.
- Cash and marketable securities in the trust account were $254.3 million, compared with $253.0 million at December 31, 2018.
- Total assets were $255.2 million; total liabilities were $8.9 million, including $7.875 million of deferred underwriting commissions.
- Stockholders’ equity was approximately $5.0 million. Public shares subject to possible redemption were recorded as temporary equity at $241.4 million.
- The company had no long-term debt, capital leases, operating leases, or off-balance-sheet arrangements. Prior sponsor loans of $270,531 had been fully repaid in February 2018.
Material Changes Versus the Prior Comparable Period
- Net income increased to $825,598 from $220,333, primarily because interest income rose to $1.464 million from $365,000 as the trust account was invested for a full comparable period.
- General and administrative expenses increased to $291,443 from $50,709, reflecting higher public-company compliance and due-diligence costs.
- State franchise tax expense increased to $49,915 from $21,818.
- Operating cash usage improved modestly to $360,587 from $380,187, but remained negative.
- Trust-account assets increased by approximately $1.3 million, principally from investment income, while operating cash declined by approximately $202,000 during the quarter.
- Shares subject to possible redemption increased to 24,137,548 from 24,054,988, reflecting the allocation of additional trust-account income to redeemable public shares.
Guidance, Outlook, Risks and Unusual Items
- Management stated that the company would not generate operating revenue until completion of an initial business combination.
- The company continued searching for a target and had broad discretion over the use of funds for identifying, evaluating, negotiating and completing a transaction.
- Management disclosed substantial doubt regarding the company’s ability to continue as a going concern because of the mandatory liquidation requirement if a business combination is not completed by February 21, 2020.
- If liquidation occurs, public shareholders are generally entitled to a pro rata distribution from the trust account, net of permitted taxes and dissolution expenses. Warrants may expire worthless and do not receive trust-account distributions.
- Public shareholders may redeem shares in connection with a business combination, subject to applicable limits, including a general 15% redemption limitation for a shareholder and affiliated group without company consent.
- Deferred underwriting commissions of $7.875 million are payable only if a business combination is completed and are waived if the company liquidates.
- Deerfield Management had indicated nonbinding interest in purchasing up to $100 million of shares in a private placement concurrent with a business combination; the company was not obligated to complete that sale.
- Related-party arrangements included monthly payments of $10,000 to the sponsor and $7,500 to the chief financial officer until the earlier of a business combination or liquidation.
- No legal proceedings, material changes to previously disclosed risk factors, defaults, or subsequent events requiring adjustment or disclosure were reported.
- Disclosure controls and procedures were assessed as effective, with no material change in internal control over financial reporting during the quarter.
Key Facts Investors Should Verify
- Confirm the issuer identity: the filing is for DFB Healthcare Acquisitions Corp., not AdaptHealth Corp.
- Verify whether a business combination was completed by the February 21, 2020 deadline and the resulting treatment of public shares, warrants and trust-account funds.
- Review the composition, restrictions and permitted uses of the $254.3 million trust account.
- Assess the impact of the $7.875 million deferred underwriting commission and potential redemption activity on funds available to shareholders.
- Evaluate the company’s ability to fund expenses outside the trust account, given only $744,766 of operating cash and continuing monthly related-party fees.
- Review sponsor incentives, related-party payments, possible working-capital loans and the potential dilution from approximately 12.7 million warrants.